Nivolumab, a Double-Edged Sword: A Case Report of Nivolumab-Induced Myasthenia Gravis

Nivolumab is a checkpoint inhibitor approved to treat various solid organs malignancies. Although checkpoint inhibitors are very efficacious, these medications are also associated with a variety of side effects that could be life-threatening. We present a case of nivolumab-induced myasthenia gravis...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahir, Nayha, Mahboob, Anber, Piao, Xuanzhen, Ying, Grace, Shrestha, Jishna, Sherchan, Robin, Zahra, Farha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510662/
https://www.ncbi.nlm.nih.gov/pubmed/34691341
http://dx.doi.org/10.14740/jmc3783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510662/
https://www.ncbi.nlm.nih.gov/pubmed/34691341
http://dx.doi.org/10.14740/jmc3783

Ejemplares similares